An observational study in Ovarian Neoplasms, Breast Neoplasms and Colorectal Neoplasms, sponsored by Medical University of Vienna. Recruiting at 6 sites in 4 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-23.
Sponsored by Medical University of Vienna · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 189 studies in Ovarian Neoplasms with a site in Germany — 34 open to participants now, 54 under way, 19 of them phase 3. Ovarian Neoplasms · Germany.
Among the 189 studies in Ovarian Neoplasms with a site in Germany, this one is the 2nd largest by planned enrollment of the 23 observational ones that give a count, is one of 5 that started in 2003, is one of 23 observational ones, reaches primary completion later than 13 of the 53 other live ones, and was the 73rd registered.
3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.
Browse Ovarian Neoplasms studies →34 of the 189 studies in Ovarian Neoplasms with a site in Germany are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United States, Australia and 10 more countries
Ages 18+ · Women only
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Sites in Germany, United States, Argentina and 19 more countries
Ages 18+ · Women only
Genmab · Sites in Germany, United States, Australia and 13 more countries
Ages 18+ · Women only
Boehringer Ingelheim · Sites in Germany, United States, Belgium and 3 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in Germany, United States, Argentina and 27 more countries
Ages 18+ · Women only
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
189 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 36 · Phase 2 74 · Phase 3 62 · Phase 4 1
First in 1995; this study’s year is marked. 5 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10,000 is above the median of 200 across 617 observational studies indexed under Ovarian Neoplasms.
Median enrollment 250 across the 163 interventional studies, 530 across the 23 observational. Of the 120 that completed or were terminated, 41 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
113 of 189 have an industry lead sponsor. The 10 most frequent:
Medical University of Vienna is the lead sponsor of 1,111 studies on the registry; 186 are open to participants now.
Medical University of Vienna has 6 studies filed under Ovarian Neoplasms — fewer than ten, so there is no comparison to draw.
11 of the studies in Ovarian Neoplasms with a site in Germany that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
| NCT05445778Phase 3AbbVieMirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer | 2027-04 |
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
| NCT07214779Phase 3Incyte CorporationStudy to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression | 2027-10-12 |
| NCT01789229Medical University of ViennaEstablishment of a Tumor Bank for Tissue Samples | 2026-12 |
Add all 11 to your calendar (.ics) → With an account.
Among the 189 studies in Ovarian Neoplasms with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Establishment of a tumor bank, consisting of blood samples of tumor patients and healthy people as controls. The blood samples will be collected systematically together with the corresponding clinical data. The biological samples, the clinical date together with prospective experimental date constitute the entity of the tumor bank.
Recent progress in diagnosis and therapy of cancer diseases can be ascribed mainly to translational research. The relevance of "translational oncology" will only increase in the future -"From bench to bedside" - the swift implementation of new science research results in clinical studies in order to expedite progress in clinical cancer therapy for the benefit of the patient.
Its almost a matter of course in the medical science today to collect biological samples together with clinical information thereby creating the foundation for future excellent fundamental research.
The aim of this tumor bank is to consist of biological samples (together with a tissue bank - see EK 260/2003) and isolates of tumor patients and healthy people as controls. The biological samples, the clinical date together with prospective experimental date constitute the entity of the tumor bank. The content of the tumor bank can provide essential material for current and future research (e.g. analyses of prognostic or predictive tumor markers; genetically analysis (polymorphism, mutation, hypermethylation; verification and characterisation of disseminated tumor cells).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who have one of the Neoplasms stated above under "conditions". Blood samples will be taken.
Other: Blood collection
Patients with a benign tumor or an inflammatory disease - to be matched by age and affected organ with a patient with a malignant disease. Blood samples will be taken.
Other: Blood collection
People/patients who have no known disease at time of blood sampling or are admitted to the hospital for minor interventions and have no inflammatory disease. Blood samples will be taken.
Other: Blood collection
Blood sample is collected during routine blood collection by a medical doctor. No more than 60ml (max.) at one timepoint.
Establishment of blood/tissue bank consisting of oncological samples from cancer patients and benign and healthy controls.
Time frame: 14 years
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
The record gives a start of Nov 2003, a primary completion of Dec 2026 and a completion of Dec 2026. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Vienna →